TY  - JOUR
AU  - Lin, Yuling
AU  - Li, Jieyu
AU  - Li, Zengyi
AU  - Ji, Yinxi
AU  - Zhou, Xiaoguo
TI  - Association of serum IL-6,IL-1beta and gene polymorphisms with pulmonary infection and prognosis of patients with type 2 diabetes mellitus
JF  - ZHONGGUO RENMIN JIEFANGJUN ZONGYIYUAN / CHINESE JOURNAL OF NOSOCOMIOLOGY
J2  - ZHONGGUO RENMIN JIEFANGJUN ZONGYIYUAN / CHINESE J NOSOCOMIOL
VL  - 33
PY  - 2023
IS  - 7
SP  - 1030
EP  - 1034
PG  - 5
SN  - 1005-4529
UR  - https://m2.mtmt.hu/api/publication/34535774
ID  - 34535774
LA  - Chinese
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Merész, Gergő
AU  - Szabó, Szilvia
AU  - Dóczy, Veronika
AU  - Hölgyesi, Áron
AU  - Szakács, Zsolt
TI  - A húgyúti fertőzések relatív gyakorisága metforminnal és SGLT2-gátlóval kezelt 2-es típusú diabetes mellitusban szenvedő betegekben : Hálózati metaanalízis
JF  - ORVOSI HETILAP
J2  - ORV HETIL
VL  - 161
PY  - 2020
IS  - 13
SP  - 491
EP  - 501
PG  - 11
SN  - 0030-6002
DO  - 10.1556/650.2020.31690
UR  - https://m2.mtmt.hu/api/publication/31258238
ID  - 31258238
AB  - Introduction and aim: The of this research was to conduct a network meta-analysis based on a systematic literature search to compare the relative frequency of urinary tract infections using sodium-glucose cotransporter-2 (SGLT2) inhibitors combined with metformin in the therapy of type 2 diabetes. Method: MEDLINE and EMBASE databases were searched to identify publications of randomized, controlled trials investigating SGLT2 inhibitors combined with metformin in the therapy of type 2 diabetes and providing information on the frequency of urinary tract infections. Results: 10 165 unique citations were screened to identify 10 publications to be included in the network meta-analysis. The network meta-analysis showed reduced risk of urinary tract infections for low-dose ertugliflozin compared to other SGLT2 inhibitors (ertugliflozin 5 mg vs. empagliflozin 10 mg: RR: 0.606, 95% CrI: 0.264-1.415; ertugliflozin 5 mg vs. dapagliflozin 10 mg: RR = 0.853, 95% CrI: 0.301-2.285). For high-dose comparisons, empagliflozin 25 mg showed reduced risk of urinary tract infections compared to both ertugliflozin 15 mg (RR = 0.745, 95% CrI 0.330-1.610) and dapagliflozin 10 mg (RR = 0.680, 95% CrI: 0.337-1.289). The difference between active substances and their doses was not statistically significant for the relative frequency of urinary tract infections. The meta-regression revealed a statistically significant association between baseline fasting plasma glucose level and relative frequency of urinary tract infections (β = 0.785, 95% CrI: 0.062-1.587). Conclusion: There was no statistically significant difference between SGLT2 inhibitors investigated in this study in terms of the relative frequency of urinary tract infections. This research demonstrates the applicability of network meta-analyses when assessing the relative effectiveness and safety of interventions. Orv Hetil. 2020; 161(13): 491-501.
LA  - Hungarian
DB  - MTMT
ER  -